Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Website: abeonatherapeutics.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 20.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -2 150.0%. On average the margin is decreasing steadily. Gross margin is high, +65.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.25 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -44.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 104.4% higher than minimum and 90.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -102.5x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $0.2 mln (0.806% of cap.)

Key Financials (Download financials)

Ticker: ABEO
Share price, USD:  (+13.0%)4.6
year average price 4.81  


year start price 3.28 2023-05-06

min close price 2.96 2023-05-17

max close price 8.68 2024-03-06

current price 4.60 2024-05-04
Common stocks: 6 421 245

Dividend Yield:  0.0%
Last revenue growth (y/y):  > 200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  20.2%
Historical growth of EBITDA:  0.0%
EV / Sales: 7.9x
Margin (EBITDA LTM / Revenue): -2 150.0%
Fundamental value created in LTM:
Market Cap ($m): 30
Net Debt ($m): 2
EV (Enterprise Value): 32
Price to Book: 2.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-02Seeking Alpha

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL

2024-04-23Seeking Alpha

Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost

2024-04-22Reuters

US FDA declines to approve Abeona's skin disorder treatment

2023-11-27Proactive Investors

Abeona Therapeutics stock climbs after drug candidate receives FDA Priority Review

2023-10-06InvestorPlace

The 7 Most Undervalued Penny Stocks to Buy in October 2023

2023-09-12InvestorPlace

3 Biotech Blockbusters to Turn $5,000 Into $50,000

2023-09-07GlobeNewsWire

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

2023-08-12Seeking Alpha

Abeona Therapeutics Inc. (ABEO) Q2 2023 Earnings Call Transcript

2023-06-05PennyStocks

3 Penny Stocks To Watch Before Next Week; Time To Buy?

2023-05-22GlobeNewsWire

Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ABEO ABEO ABEO ABEO ABEO ABEO ABEO
reportedCurrency USD USD USD USD USD USD USD
cik 318 306 318 306 318 306 318 306 318 306 318 306 318 306
fillingDate 2024-03-18 2023-11-13 2023-08-08 2023-05-11 2023-03-29 2022-11-14 2022-08-11
acceptedDate 2024-03-18 07:35:57 2023-11-13 08:01:04 2023-08-08 07:30:56 2023-05-11 07:30:55 2023-03-29 07:30:53 2022-11-14 08:30:36 2022-08-11 07:40:58
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 4M 0 68 000 0 1 000 000
costOfRevenue 721 000 751 000 2M 0 100 000 0 350 000
grossProfit -721 000 -751 000 2M 0 -32 000 0 650 000
grossProfitRatio 0 0 0.550 0 -0.471 0 0.650
researchAndDevelopmentExpenses 7M 7M 9M 8M 6M 5M 7M
generalAndAdministrativeExpenses 6M 4M 5M 4M 6M 4M 3M
sellingAndMarketingExpenses -721 000 -721 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 3M 5M 4M 6M 4M 3M
otherExpenses 214 000 111 000 2M 403 000 277 000 0 0
operatingExpenses 12M 11M 14M 12M 12M 9M 10M
costAndExpenses 13M 11M 15M 12M 12M 9M 10M
interestIncome 743 000 593 000 417 000 364 000 328 000 72 000 30 000
interestExpense 109 000 105 000 103 000 101 000 178 000 157 000 317 000
depreciationAndAmortization 721 000 751 000 838 000 767 000 3M 1M 1M
ebitda -12M -11M -8M -11M -10M -8M -7M
ebitdaratio 0 0 -2.328 0 -152.529 0 -6.608
operatingIncome -13M -11M -11M -12M -13M -9M -8M
operatingIncomeRatio 0 0 -3.015 0 -190.235 0 -8.008
totalOtherIncomeExpensesNet -3M -502 000 -5M 3M 12M -104 000 -287 000
incomeBeforeTax -17M -12M -17M -9M -1M -9M -8M
incomeBeforeTaxRatio 0 0 -4.758 0 -16.559 0 -8.295
incomeTaxExpense 0 0 2M -3M -8M 104 000 0
netIncome -17M -12M -17M -6M 6M -10M -8M
netIncomeRatio 0 0 -4.758 0 94.338 0 -8.295
eps -0.650 -0.480 -0.920 -0.740 0.820 -1.490 -52.000
epsdiluted -0.650 -0.480 -0.920 -0.740 0.820 -1.490 -52.000
weightedAverageShsOut 26M 25M 18M 8M 8M 6M 232 258
weightedAverageShsOutDil 26M 25M 18M 8M 8M 6M 232 258
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ABEO ABEO ABEO ABEO ABEO ABEO ABEO
reportedCurrency USD USD USD USD USD USD USD
cik 318 306 318 306 318 306 318 306 318 306 318 306 318 306
fillingDate 2024-03-18 2023-11-13 2023-08-08 2023-05-11 2023-03-29 2022-11-14 2022-08-11
acceptedDate 2024-03-18 07:35:57 2023-11-13 08:01:04 2023-08-08 07:30:56 2023-05-11 07:30:55 2023-03-29 07:30:53 2022-11-14 08:30:36 2022-08-11 07:40:58
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 15M 5M 6M 5M 14M 6M 6M
shortTermInvestments 38M 49M 31M 36M 38M 12M 14M
cashAndShortTermInvestments 53M 54M 37M 40M 52M 18M 20M
netReceivables 2M 2M 6M 519 000 188 000 1M 3M
inventory 0 338 000 338 000 338 000 338 000 0 0
otherCurrentAssets 729 000 963 000 1M 2M 424 000 945 000 7M
totalCurrentAssets 56M 57M 44M 43M 53M 25M 30M
propertyPlantEquipmentNet 8M 9M 9M 10M 11M 13M 14M
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 276 999 139 000 108 000 99 000 43 000 20 000 20 000
totalNonCurrentAssets 8M 9M 10M 11M 11M 13M 14M
otherAssets 0 0 0 0 0 0 0
totalAssets 64M 66M 54M 53M 64M 39M 45M
accountPayables 2M 3M 3M 3M 2M 2M 2M
shortTermDebt 998 000 2M 2M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 0 4M 4M 0 0 0 0
otherCurrentLiabilities 11M 199 000 205 000 3M 4M 9M 10M
totalCurrentLiabilities 13M 8M 9M 7M 8M 13M 14M
longTermDebt 4M 4M 4M 6M 6M 6M 7M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 31M 32M 30M 22M 24M 7M 4M
totalNonCurrentLiabilities 36M 36M 35M 27M 30M 11M 11M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 4M 6M 6M 7M 8M 8M 9M
totalLiabilities 49M 44M 44M 35M 37M 23M 25M
preferredStock 0 0 0 0 0 0 0
commonStock 265 000 247 000 215 000 179 000 177 000 77 000 1M
retainedEarnings -750M -733M -721M -704M -695M -694M -685M
accumulatedOtherComprehensiveIncomeLoss -66 000 -99 000 -95 000 -65 000 -129 000 -44 000 -34 000
othertotalStockholdersEquity 764M 755M 730M 723M 722M 710M 703M
totalStockholdersEquity 15M 22M 9M 19M 27M 15M 20M
totalEquity 15M 22M 9M 19M 27M 15M 20M
totalLiabilitiesAndStockholdersEquity 64M 66M 54M 53M 64M 39M 45M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 64M 66M 54M 53M 64M 39M 45M
totalInvestments 38M 49M 31M 36M 38M 12M 0
totalDebt 5M 6M 6M 7M 8M 8M 9M
netDebt -9M 980 000 -251 000 3M -7M 3M 2M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ABEO ABEO ABEO ABEO ABEO ABEO ABEO
reportedCurrency USD USD USD USD USD USD USD
cik 318 306 318 306 318 306 318 306 318 306 318 306 318 306
fillingDate 2024-03-18 2023-11-13 2023-08-08 2023-05-11 2023-03-29 2022-11-14 2022-08-11
acceptedDate 2024-03-18 07:35:57 2023-11-13 08:01:04 2023-08-08 07:30:56 2023-05-11 07:30:55 2023-03-29 07:30:53 2022-11-14 08:30:36 2022-08-11 07:40:58
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -17M -12M -17M -9M -1M -9M -8M
depreciationAndAmortization 721 000 751 000 838 000 888 000 1M 1M 1M
deferredIncomeTax -792 999 1M 8M 0 0 0 0
stockBasedCompensation 2M 2M 927 000 770 000 833 000 632 000 724 000
changeInWorkingCapital 1M 2M -3M -2M -4M 834 000 -2M
accountsReceivables -20 000 4M -4M 0 2M 1 000 000 -1 000 000
inventory -1.000 1M 0 0 0 0 0
accountsPayables 2M -1M 2M -684 000 -5M -1M 702 000
otherWorkingCapital -1M -1M -2M 684 000 -639 000 1M 0
otherNonCashItems 5M 313 000 147 000 -2M -11M 142 000 -1M
netCashProvidedByOperatingActivities -9M -6M -10M -12M -14M -7M -9M
investmentsInPropertyPlantAndEquipment -37 000 -44 000 -32 000 -218 000 -25 000 -2000.000 0
acquisitionsNet 17 000 44 000 32 000 0 0 0 0
purchasesOfInvestments -3M -34M -6M -8M -34M -9M -27M
salesMaturitiesOfInvestments 15M 15M 11M 10M 9M 11M 24M
otherInvestingActivites 12M -36 000 147 000 0 144 000 103 000 1M
netCashUsedForInvestingActivites 12M -19M 5M 2M -25M 2M -1M
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 8M 23M 1 657M 0 43M 4M 22M
commonStockRepurchased -182 000 0 4000.000 -4000.000 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -137 000 -4000.000 -1 650M 0 -5000.000 0 -26M
netCashUsedProvidedByFinancingActivities 7M 23M 7M -4000.000 43M 4M -4M
effectOfForexChangesOnCash 0 -9M 1 656M 0 0 0 0
netChangeInCash 10M -2M 2M -10M 3M -953 000 -8M
cashAtEndOfPeriod 15M 5M 7M 5M 15M 11M 12M
cashAtBeginningOfPeriod 5M 7M 5M 15M 11M 12M 20M
operatingCashFlow -9M -6M -10M -12M -14M -7M -9M
capitalExpenditure -37 000 -44 000 -32 000 -218 000 -25 000 -2000.000 0
freeCashFlow -9M -6M -10M -12M -14M -7M -9M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2023 q3
2023-11-16 ET (fiscal 2023 q3)
2023 q2
2023-08-12 ET (fiscal 2023 q2)
2023 q1
2023-05-24 ET (fiscal 2023 q1)
2022 q1
2022-05-17 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-03-18 11:30 ET
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
2024-03-05 12:30 ET
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 21:05 ET
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 12:30 ET
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
2024-01-08 12:30 ET
Abeona Therapeutics Announces $50 Million Credit Facility
2023-12-15 12:30 ET
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-27 12:30 ET
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
2023-11-13 12:30 ET
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
2023-11-01 11:30 ET
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-26 11:30 ET
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
2023-09-12 11:30 ET
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
2023-09-07 11:30 ET
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
2023-08-30 11:30 ET
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
2023-08-08 11:30 ET
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
2023-07-28 11:30 ET
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
2023-07-19 12:30 ET
Abeona Therapeutics Joins Rare Disease Company Coalition
2023-07-03 12:45 ET
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-06-09 11:30 ET
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
2023-06-01 11:30 ET
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
2023-05-22 11:30 ET
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
2023-05-16 13:00 ET
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2023-05-11 11:30 ET
Abeona Therapeutics Reports First Quarter 2023 Financial Results
2023-05-11 11:00 ET
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
2023-04-10 11:30 ET
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2023-03-29 11:30 ET
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
2023-03-24 11:30 ET
Abeona Therapeutics Announces New Employee Inducement Grants
2023-03-16 11:30 ET
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
2023-03-14 11:30 ET
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
2022-11-14 12:30 ET
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
2022-11-03 11:31 ET
Abeona Therapeutics Announces $35 Million Private Placement Financing
2022-11-03 11:30 ET
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
2022-10-19 11:30 ET
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
2022-10-04 11:30 ET
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
2022-09-22 11:30 ET
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
2022-09-13 11:30 ET
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
2022-08-11 11:30 ET
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
2022-07-20 11:30 ET
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
2022-06-06 11:30 ET
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
2022-05-19 11:30 ET
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
2022-05-17 12:00 ET
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
2022-05-13 11:30 ET
Abeona Therapeutics Reports First Quarter 2022 Financial Results
2022-05-04 11:30 ET
Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates
2022-04-29 13:00 ET
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2022-04-29 11:30 ET
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock
2022-03-31 11:30 ET
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
2022-03-28 15:20 ET
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
2022-03-14 11:30 ET
Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB
2021-12-22 12:30 ET
Abeona Therapeutics Issues Letter to Shareholders
2021-12-17 14:00 ET
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
2021-12-16 21:01 ET
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
2021-11-18 12:30 ET
Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa
2021-11-17 12:30 ET
Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
2021-11-16 12:30 ET
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
2021-11-15 12:45 ET
Abeona Therapeutics Reports Third Quarter Financial Results
2021-10-21 11:30 ET
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
2021-10-13 11:30 ET
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
2021-10-12 11:30 ET
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
2021-09-21 20:01 ET
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
2021-09-07 11:30 ET
Abeona Therapeutics to Present at Upcoming Investor Conferences
2021-08-10 11:30 ET
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
2021-07-28 20:01 ET
Abeona Therapeutics Reports Second Quarter Financial Results
2021-07-28 11:30 ET
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
2021-07-26 11:30 ET
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
2021-07-23 11:30 ET
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
2021-07-07 11:30 ET
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
2021-06-02 11:30 ET
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
2021-05-26 11:30 ET
Abeona Therapeutics Issues Letter to Stockholders
2021-05-25 11:30 ET
Abeona Therapeutics Appoints Head of Research & Clinical Development
2021-05-18 11:30 ET
Abeona Therapeutics Reports First Quarter Financial Results
2021-04-20 11:30 ET
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
2021-04-19 11:30 ET
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
2021-03-25 11:30 ET
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
2021-03-24 20:01 ET
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
2021-03-22 11:30 ET
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
2021-02-22 12:30 ET
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2021-02-12 16:36 ET
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
2021-02-02 12:30 ET
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
2021-01-25 12:30 ET
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
2020-12-21 17:20 ET
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
2020-11-09 21:05 ET
Abeona Therapeutics Reports Third Quarter Financial Results
2020-10-27 10:30 ET
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
2020-10-06 20:01 ET
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
2020-09-28 13:27 ET
Abeona Therapeutics Announces Leadership and Board Transitions
2020-09-08 20:05 ET
Abeona Therapeutics to Participate in Upcoming Investor Conferences
2020-08-17 11:00 ET
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
2020-08-10 20:01 ET
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
2020-08-10 20:01 ET
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
2020-07-10 11:30 ET
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
2020-07-09 11:30 ET
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
2020-07-08 11:30 ET
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
2020-06-18 11:30 ET
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
2020-06-17 11:30 ET
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
2020-05-28 12:30 ET
Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
2020-05-06 20:14 ET
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
2020-05-06 20:14 ET
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
2020-04-21 20:04 ET
Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2020-04-21 12:00 ET
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors
2020-03-27 22:19 ET
Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic
2020-03-27 22:19 ET
Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic
2020-03-17 11:30 ET
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
2020-03-16 20:20 ET
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates
2020-02-26 13:00 ET
Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-12 19:15 ET
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™
2020-01-21 13:00 ET
Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa
2020-01-15 14:32 ET
Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids
2020-01-13 14:00 ET
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
2019-12-24 18:01 ET
Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2019-12-20 14:23 ET
Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants
2019-12-20 13:26 ET
Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA
2019-12-19 22:20 ET
Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
2019-12-09 13:45 ET
Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
2019-11-12 21:30 ET
Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
2019-11-10 19:00 ET
ROSEN, A LEADING GLOBAL LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Abeona Therapeutics Inc. - ABEO
2019-10-21 13:15 ET
Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
2019-10-15 13:15 ET
Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
2019-09-23 12:45 ET
Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa
2019-04-04 12:25 ET
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
2019-03-18 20:45 ET
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-22 13:01 ET
Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 8
2024-05-03 00:00 ET
Abeona Therapeutics published news for 2024 q1
SEC form 8
2024-03-18 08:36 ET
Abeona Therapeutics published news for 2023 q4
SEC form 8
2024-03-18 08:36 ET
Abeona Therapeutics reported for 2023 q4
SEC form 10
2024-03-18 07:35 ET
Abeona Therapeutics reported for 2023 q4
SEC form 10
2024-03-18 00:00 ET
Abeona Therapeutics reported for 2023 q4
SEC form 10
2023-11-13 08:01 ET
Abeona Therapeutics reported for 2023 q3
SEC form 8
2023-11-13 07:35 ET
Abeona Therapeutics reported for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Abeona Therapeutics reported for 2023 q3
SEC form 6
2023-08-08 08:30 ET
Abeona Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 07:30 ET
Abeona Therapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Abeona Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Abeona Therapeutics reported for 2023 q2
SEC form 6
2023-07-07 08:41 ET
Abeona Therapeutics published news for 2023 q2
SEC form 6
2023-07-03 08:54 ET
Abeona Therapeutics published news for 2023 q2
SEC form 6
2023-05-17 16:30 ET
Abeona Therapeutics published news for 2023 q1
SEC form 10
2023-05-11 07:30 ET
Abeona Therapeutics reported for 2023 q1
SEC form 6
2023-05-11 07:30 ET
Abeona Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Abeona Therapeutics reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Abeona Therapeutics reported for 2023 q1
SEC form 6
2023-04-13 16:15 ET
Abeona Therapeutics published news for 2023 q1
SEC form 6
2023-04-11 16:30 ET
Abeona Therapeutics published news for 2023 q1
SEC form 6
2023-04-10 17:18 ET
Abeona Therapeutics published news for 2023 q1
SEC form 6
2023-03-29 07:35 ET
Abeona Therapeutics reported for 2022 q4
SEC form 10
2023-03-29 07:30 ET
Abeona Therapeutics reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Abeona Therapeutics reported for 2022 q4
SEC form 8
2023-03-29 00:00 ET
Abeona Therapeutics reported for 2022 q4
SEC form 6
2023-03-13 07:00 ET
Abeona Therapeutics published news for 2022 q4
SEC form 10
2022-11-14 00:00 ET
Abeona Therapeutics reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Abeona Therapeutics reported for 2022 q3
SEC form 10
2022-08-11 00:00 ET
Abeona Therapeutics reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Abeona Therapeutics reported for 2022 q2
SEC form 8
2022-05-13 00:00 ET
Abeona Therapeutics reported for 2022 q1
SEC form 10
2022-05-13 00:00 ET
Abeona Therapeutics reported for 2022 q1
SEC form 10
2022-03-31 00:00 ET
Abeona Therapeutics published news for 2021 q4
SEC form 8
2022-03-31 00:00 ET
Abeona Therapeutics published news for 2021 q4
SEC form 10
2021-11-15 00:00 ET
Abeona Therapeutics published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
Abeona Therapeutics published news for 2021 q3
SEC form 10
2021-07-28 00:00 ET
Abeona Therapeutics published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
Abeona Therapeutics published news for 2021 q2
SEC form 8
2021-05-26 00:00 ET
Abeona Therapeutics published news for 2021 q1
SEC form 8
2021-05-18 00:00 ET
Abeona Therapeutics published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
Abeona Therapeutics published news for 2021 q1